The global brain tumor diagnosis and therapeutics market was valued at USD 3,255.60 million in 2024 and is expected to reach USD 3,481.87 million in 2025. The market is projected to expand significantly, reaching USD 6,509.72 million by 2034, reflecting a compound annual growth rate (CAGR) of 7.2% over the forecast period from 2025 to 2034.

Key Market Trends

Advancements in Diagnostic Technologies

MRI and CT Scans : Continued dominance as primary imaging tools with AI integration for faster, more accurate diagnosis.
Liquid Biopsy & Biomarkers : Rising adoption of liquid biopsies and molecular biomarkers (e.g., IDH1/2, MGMT promoter methylation) for early detection and tumor subtyping.
AI & Machine Learning : Enhancing image interpretation and predictive analytics for tumor classification.

Personalized Medicine and Targeted Therapies

Increasing use of genomic profiling to tailor treatment strategies.
Development of targeted therapies based on specific mutations (e.g., EGFR, BRAF).
Companion diagnostics playing a critical role in guiding therapeutic decisions.

Growth in Immunotherapy and Gene Therapy

Checkpoint inhibitors , CAR-T cell therapy , and oncolytic virus therapy gaining traction in clinical trials.
Gene-editing technologies like CRISPR offering new hope for treating aggressive brain tumors such as glioblastoma multiforme (GBM).

Minimally Invasive Surgical Techniques

Adoption of robotic-assisted surgery , laser interstitial thermal therapy (LITT) , and stereotactic radiosurgery (e.g., Gamma Knife).
These techniques reduce recovery time and improve patient outcomes.

Market Size & Forecast

Market Size in 2025 – USD 3,481.87 million
Projected Market Size by 2034 – USD 6,509.72 million
CAGR (2025–2034) – 7.2%

Request a free sample copy or view report summary: https://www.polarismarketresearch.com/industry-analysis/global-brain-tumor-diagnosis-and-therapeutics-market/request-for-sample

Market Overview

The brain tumor diagnosis and therapeutics market has entered a period of dynamic transformation, driven by rapid advancements in neuroimaging technologies, personalized medicine, and targeted therapies. As the incidence of primary and secondary brain tumors continues to rise globally, so too does the demand for early detection tools, minimally invasive treatment modalities, and precision oncology solutions. The market is currently witnessing robust growth, supported by increased healthcare spending, expanding R&D pipelines, and growing patient awareness regarding neurological disorders. According to recent epidemiological data from the World Health Organization (WHO) and the Central Brain Tumor Registry of the United States (CBTRUS), approximately 85,000 new cases of primary brain and central nervous system (CNS) tumors were diagnosed in the U.S. alone in 2023, with global figures expected to rise steadily over the next decade.

This growing disease burden has catalyzed significant investment across both public and private sectors into advanced diagnostic platforms such as MRI, PET-CT, and liquid biopsy-based biomarker testing, all of which are instrumental in improving diagnostic accuracy and enabling earlier intervention. Simultaneously, therapeutic innovation is accelerating, particularly in the fields of immunotherapy, gene therapy, and oncolytic virotherapy—areas where clinical trial activity has surged in recent years. The U.S. Food and Drug Administration (FDA) has approved several novel agents under accelerated pathways, reflecting an evolving regulatory environment that encourages expedited development for high-impact oncology indications.